Reliable Quality

Affordable Innovation

Research Progress

Up to date, in addition to two products launched commercially and one product under NDA review, Henlius has conducted over 20 clinical studies for 10 products and 8 combination therapies worldwide. 漢利康® (HLX01, rituximab injection), the first product of Henlius, has been approved by the NMPA as China’s first biosimilar in February 2019. The second product 漢曲優® (HLX02, trastuzumab injection, Zercepac® in the EU) was launched both in China and Europe in 2020, becoming the first Chinese mAb biosimilar entering both the EU and China market. It will bring more treatment options to patients with HER2 positive breast and gastric cancer worldwide.HLX03 (adalimumab injection) was also accepted for NDA review and assigned to priority review list by the NMPA.

Products in R&D
Target
Generic Name
Study Phase
Potential Indication
Study Phase
Product Pipeline

With the efficient and innovative in-house capabilities, Henlius has developed a diversified and advanced drug pipeline with a focus in the fields of oncology, autoimmune diseases etc. 

                             
hg320挂赚钱宝网络卡 天湖北快三预测号 二分时时彩全天计划 排列五类型走势图新浪 今日山西快乐十分走势 幸运农场安卓版下载 上海快三计划论坛 彩票深圳风采开奖结果查询 幸运飞艇双面盘计划 加拿大快乐8预测 秒速赛车计划网页 台灣股票融资利率 七i星彩开奖结果 排列七开奖 河北11选五一定牛遗漏数据 大单网 黑龙江快乐十分投注规则